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Abstract
Introduction: Minocycline and doxycycline are safe and moderately effective disease-modifying anti-rheumatic
drugs (DMARDs) in the treatment of early, DMARD-naïve rheumatoid arthritis (RA), although little is known about
their use outside clinical trials. We characterize the use of minocycline and doxycycline in community-dwelling RA
patients by examining associated prescribing patterns, patient-level determinants of use, and side-effect profiles.
Methods: We studied 15,716 patients with RA observed between 1998 and 2009 while participating in a long-term
US observational study.
Results: Minocycline or doxycycline was prescribed by 18% of rheumatologists (interquartile range one to two
patients per physician) to 9% of RA patients. Significant differences between minocycline-treated and doxycycline-
treated patients and nontreated patients included age (58.4 years vs. 59.8 years), RA duration (14.8 years vs. 13.7
years), Caucasian race (93.7% vs. 89.7%), lifetime DMARDs and biologics (3.3 vs. 2.5), prednisone use (40.1% vs.
35.3%), and Medical Outcomes Study 36-Item Short Form Survey physical component summary score (35.0 vs.
36.4). In multivariable Cox regression, patients initiating minocycline or doxycycline had increased disease activity,
more comorbidities, and a greater number of prior nonbiologic DMARDs. Side effects were reported by 17.8% of
minocycline users and 11.8% of doxycycline users. Skin complaints accounted for 54% of minocycline patient-
reported side effects. The most commonly effected organ systems for doxycycline were gastrointestinal (35.4%) and
skin (33.7%). Approximately 75% of side effects were of mild or moderate severity.
Conclusions: Rheumatologists have not embraced minocycline or doxycycline as primary treatment options for RA
and reserve their use primarily in patients with long-standing, refractory disease. These drugs are generally well
tolerated, with skin complaints, nausea, and dizziness being the most common patient-reported side effects.
Introduction
Minocycline and doxycycline are semi-synthetic tetracy-
cline antibiotics with anti-inflammatory properties that
are used to treat multiple inflammatory diseases, includ-
ing rheumatoid arthritis (RA) [1,2]. Tetracyclines exhibit
multiple anti-inflammatory properties, including the
inhibition of T-cell activation and chemotaxis, the
downregulation of proinflammatory cytokines, including
TNFa and IL-1b [1-3], and the inhibition of matrix
metalloproteinases [4-6].
Minocycline has proven to be a very safe and moder-
ately effective disease-modifying antirheumatic drug
(DMARD) in the treatment of RA, but its efficacy
appears to vary greatly depending on the patient popula-
tion in which it is used. Although an initial open-label
study using minocycline in treatment-resistant RA was
encouraging [7], two subsequent double-blind, placebo-
controlled studies from the 1990s found only modest,
although statistically significant, clinical improvement.
The participants in these latter two trials had long-
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standing, DMARD-refractory disease [8,9]. In contrast,
more recent trials examining minocycline in DMARD-
naïve, early RA yielded more impressive results. In sepa-
rate studies, minocycline showed superior efficacy and
similar tolerability to placebo [10,11] and hydroxychlor-
oquine [12].
Reports of doxycycline in the treatment of RA have
also been inconsistent, with two studies showing no
treatment benefit in patients with established disease
[13,14] while a more recent study of patients with early
disease showed significant efficacy compared with pla-
cebo when used in combination with methotrexate [15].
The benefit of minocycline and doxycycline was con-
firmed in a recent meta-analysis that found clinically
significant improvement in disease activity with no
increased risk for adverse events, although the authors
note that the overall number and quality of clinical trials
was low [16].
Although these studies indicate that minocycline and
doxycycline represent important options in the treat-
ment of RA, particularly among patients with recent-
onset seropositive disease, little is known about how
these medications are utilized outside the context of
clinical trials. We sought to characterize the use of min-
ocycline and doxycycline in a large community cohort
of RA patients, by examining associated prescribing pat-
terns, patient-level determinants of use, and the fre-
quency and severity of patient-reported side effects.
Materials and methods
Study participants
Patients were diagnosed with RA by their physicians and
were participants in the National Data Bank for Rheu-
matic Diseases (NDB) longitudinal observational study
of RA outcomes. NDB participants are recruited from a
large network of rheumatologists and fill out detailed,
semi-annual questionnaires, which have been previously
described [17-19]. Study participants were enrolled in
the NDB from 1998 through 2009 and were not part of
a drug safety registry as these patients may have more
severe disease and may not be representative of the gen-
eral RA population. Patients were categorized based on
exposure to minocycline and/or doxycycline and the
timing of drug initiation (prior to or after NDB
enrollment).
Study variables
The sociodemographic information analyzed includes
age, male sex, Caucasian non-Hispanic race, education
in years, total household income in US dollars, semi-
annual direct medical expenses in US dollars [20], semi-
annual expenses for all medications in US dollars, and
insurance profile (private, HMO, Medicare, PPO, Medi-
caid, or no insurance). Disease characteristics include:
duration of RA; rheumatic disease comorbidity index
(range 0 to 9) [21]; cumulative use of biologic and non-
biologic DMARDs; concomitant use of methotrexate or
prednisone; Medical Outcomes Study 36-Item Short
Form Survey physical component summary score and
mental component summary score [22]; Health Assess-
ment Questionnaire disability index [23]; pain visual
analog scale; patient global disease severity visual analog
scale; and Patient Activity Scale [24,25].
Statistical analysis
Patient sociodemographic and disease characteristics
were compared between incident minocycline and/or
doxycycline users and those never exposed using data
from their initial NDB observation. For the continuous
study variables, means and standard deviations were cal-
culated and then analyzed with unpaired t tests. For
dichotomous data, a chi-square test was performed. A
two-tailed P value of 0.05 was considered significant.
A time-to-event analysis was conducted with initiation
of either minocycline or doxycycline as the event of
interest. For this analysis, we eliminated all starters who
had taken either drug prior to NDB enrollment. Cox
proportional hazards regression models were used to
test a number of potential covariates, including demo-
graphics, disease characteristics, and drug-use history. A
final model was developed using all significant predic-
tors with age and gender included for control purposes.
A global test for violation of the proportional hazards
assumption confirmed that the assumption was not
violated.
All patients with minocycline and/or doxycycline
exposure, regardless of initiation prior to or during
NDB enrollment, were evaluated for self-reported side
effects. The prevalence of specific side effects was deter-
mined and categorized by organ system and severity.
The frequencies with which side effects led to drug dis-
continuation, dose adjustment, the addition of medica-
tions, a visit to a physician, missed work, and
hospitalization were also calculated.
The study was carried out in compliance with the Hel-
sinki Declaration, and was approved by the Institutional
Review Board of the St Francis Regional Medical Center,
Wichita, KS, USA. All patients signed an informed
consent.
Results
A total of 15,716 RA patients were evaluated (Figure 1).
Of these patients, 1,407 (9.0%) received minocycline or
doxycycline at some time during their disease course,
with 726 (4.6%) receiving either drug during direct NDB
observation. There were 480 (3.1%) incident users (mino-
cycline n = 112; doxycycline n = 345; both drugs n = 23).
Patients were seen by a total of 1,067 rheumatologists, of
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which 196 (18.4%) prescribed either treatment (minocy-
cline n = 79, doxycycline n = 162, both drugs n = 45).
The median number of patients per doctor on either
treatment was one patient (interquartile range one to two
patients). The upper decile of rheumatologists had five or
more patients on these agents. The median daily dose for
both minocycline and doxycycline was 200 mg (inter-
quartile range 100 to 200 mg). The median duration of
therapy for minocycline was 6 months (interquartile
range 2 to 15 months) and for doxycycline was 3 months
(interquartile range 1 to 6 months).
Table 1 summarizes the sociodemographic informa-
tion, RA characteristics, and concomitant medications of
patients initiating minocycline and/or doxycycline ther-
apy and those patients never exposed. Minocycline and
doxycycline users were slightly younger (58.35 years vs.
59.76 years, P = 0.021) and more commonly non-Hispa-
nic Caucasian (93.68% vs. 89.72%, P = 0.005) than nonu-
sers. They had longer duration of RA (14.77 years vs.
13.70 years, P = 0.036), an increased number of lifetime
DMARDs (2.90 vs. 2.13, P < 0.001) and lifetime com-
bined DMARD and biologic agents (3.30 vs. 2.52, P <
0.001), and were more frequently on prednisone (40.08%
vs. 35.34%, P = 0.033). Minocycline and doxycycline
users had a different insurance profile (P = 0.044) and
their mean physical component summary score was
lower (indicating worse physical functioning; 35.03 vs.
36.39, P = 0.008) compared with those without tetracy-
cline exposure. There were no other study variables that
reached statistical significance. After excluding patients
who initiated both minocycline and doxycycline during
NDB observation (n = 23), there were no significant dif-
ferences in study variables between incident minocycline
and doxycycline users (data not shown). In multivariable
Cox regression, initiation of either treatment was asso-
ciated with an increase in comorbidities, previous num-
ber of nonbiologic DMARDs, calendar year, and disease
activity (as measured by the Patient Activity Scale), and
with a decrease in previous number of biologic
DMARDs and current use of methotrexate, leflunomide,
or azathioprine (Table 2).
There were 137 side effects reported by 61 out of 342
(17.8%) minocycline users and 100 side effects reported
by 57 out of 484 (11.8%) doxycycline users. The fre-
quency and severity of specific treatment-related side
effects with minocycline and doxycycline are summar-
ized in Table 3, while the frequency and severity of
these side effects by organ system are shown in Figure
2. Minocycline side effects most commonly involved the
skin (54%); the other most common adverse minocycline
effects were dizziness (9.5%) and nausea (5.1%). The
most common doxycycline side effects were nausea
Figure 1 Rheumatoid arthritis patients with minocycline and doxycycline exposure. Flow diagram of National Data Bank for Rheumatic
Diseases (NDB) rheumatoid arthritis (RA) patients with regards to minocycline (MC) and doxycycline (DC) exposure.
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(15.5%), other skin abnormalities (10%), photosensitivity
(8.2%), and dizziness (8.2%). The majority of side effects
were classified as mild or moderate for minocycline
(70.0%) and doxycycline (76.4%).
Table 4 summarizes the patient-reported conse-
quences of medication side effects for all patients
exposed to minocycline and/or doxycycline. For minocy-
cline, adverse drug effects led to a doctor visit in 48.2%,
discontinuation in 38.2%, the use of additional medica-
tion in 32%, a dose change in 31.6%, missed work in
1.1%, and hospitalizations in 1.0% of the patients who
reported a medication side effect. For doxycycline, side
effects caused a doctor visit in 59.5%, the use of addi-
tional medication in 52.8%, discontinuation in 42.7%, a
dose change in 16.7%, missed work 6.8%, and hospitali-
zations in 1.3%.
Table 1 Patient characteristics of minocycline and doxycycline users and nonusers
Initiated MC/DC (n = 480) Never used MC/DC (n = 14,309) P value
Age (years) 58.35 (11.60) 59.76 (13.28) 0.021
Male sex (%) 20.83 22.23 0.469
Rheumatoid arthritis duration (years) 14.77 (10.92) 13.70 (11.05) 0.036
Education (years) (0 to 17) 13.70 (2.32) 13.52 (2.33) 0.106
Caucasian, non-Hispanic (%) 93.68 89.72 0.005
Income (US$) 46,698 (28,088) 46,309 (29,352) 0.775
Semi-annual costs (US$) 6,007 (10,635) 5,685 (7,835) 0.406
Semi-annual drug costs (US$) 4,073 (8,522) 3,826 (6,528) 0.098
Insurance (%) 0.044
Private 29.17 27.26
Health maintenance organization 11.25 8.64
Medicare 41.67 47.10
Preferred provider organization 10.00 9.27
Medicaid 4.79 5.77
No insurance 3.13 1.95
Lifetime DMARDs 2.90 (1.83) 2.13 (1.54) < 0.001
Lifetime DMARDs and biologics 3.30 (2.10) 2.52 (1.81) < 0.001
Prednisone (%) 40.08 35.34 0.033
Methotrexate (%) 49.48 50.48 0.667
Comorbidity index (0 to 9) 1.68 (1.46) 1.59 (1.48) 0.193
Health Assessment Questionnaire (0 to 3) 1.06 (0.71) 1.04 (0.73) 0.474
Physical component summary score (0 to 100) 35.03 (11.17) 36.39 (11.09) 0.008
Mental component summary score (0 to 100) 50.02 (11.30) 49.11 (11.49) 0.086
Patient global (0 to 10) 3.47 (2.50) 3.50 (2.53) 0.784
Pain (0 to 10) 3.92 (2.82) 3.83 (2.79) 0.506
Patient Activity Scale (0 to 10) 3.64 (2.27) 3.60 (2.24) 0.666
Data presented as mean (standard deviation). DC, doxycycline; DMARD, disease-modifying anti-rheumatic drug; MC, minocycline.
Table 2 Multivariable Cox proportional hazards model for time to initiation of minocycline or doxycycline
Hazard ratio 95% confidence interval Standard error P value
Male sex 1.139 0.887, 1.464 0.146 0.308
Age 0.990 0.982, 0.998 0.004 0.021
Number of previous nonbiologic DMARDs 1.618 1.532, 1.710 0.045 < 0.001
Methotrexate use 0.728 0.596, 0.890 0.074 0.002
Leflunomide use 0.622 0.470, 0.822 0.089 0.001
Azathioprine use 0.378 0.186, 0.769 0.137 0.007
Patient Activity Score 1.049 1.000, 1.100 0.026 0.051
Comorbidity index 1.139 1.072, 1.210 0.035 < 0.001
Number of previous biologic DMARDs 0.779 0.676, 0.898 0.057 0.001
Calendar year 1.062 1.001, 1.127 0.032 0.046
n = 11,987. DMARD, disease-modifying anti-rheumatic drug.
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Discussion
Recent investigations have provided evidence that tetra-
cyclines are moderately effective drugs in the treatment
of early RA [7-12,15,16]. Their efficacy appears to be
much less robust in long-standing disease. Despite this,
the mean duration of RA for NDB participants initiating
minocycline or doxycycline was 14.8 years; this is longer
than previous studies by Kloppenburg and colleagues
(12 ± 10 years) and Tilley and colleagues (8.4 ± 8.6
years), in which long-standing disease showed only
modest improvement with minocycline treatment [8,9].
Additionally, minocycline and doxycycline users in the
current study probably had refractory RA, as indicated
by more frequent prednisone use and increased lifetime
exposure to DMARDs and biologic agents. This was
supported by the Cox regression data, which showed
that patients initiating minocycline and/or doxycycline
had increased disease activity and greater cumulative
exposure to nonbiologic DMARDs. These findings are
similar to a small retrospective analysis of minocycline
at a community hospital, in which the mean duration of
RA was 18 years and patients had failed treatment with
Table 3 Most common rheumatoid arthritis patient-
reported side effects to minocycline and doxycycline and
their severity
Side effect Mild Moderate Severe Total (%)
Minocycline
Skin, other 7 16 11 34 (25)
Photosensitivity 2 9 4 15 (11)
Purpura 2 10 1 13 (10)
Dizziness 8 2 3 13 (10)
Rash 0 3 5 8 (6)
Nausea 1 2 4 7 (5)
Headache 1 1 3 5 (4)
Tinnitus 3 1 0 4 (3)
Diarrhea 2 1 1 4 (3)
Itching 0 2 1 3 (2)
Gastrointestinal, other 0 2 1 3 (2)
Abdominal pain 1 1 1 3 (2)
Other 11 8 6 25 (18)
Total (%) 38 (28) 58 (42) 41 (30) 137 (100)
Doxycycline
Nausea 3 10 4 17 (16)
Skin, other 7 2 2 11 (10)
Photosensitivity 2 4 3 9 (8)
Dizziness 6 2 1 9 (8)
Rash 0 5 3 8 (7)
Abdominal pain 0 5 2 7 (6)
Purpura 2 4 0 6 (6)
Diarrhea 2 2 2 6 (6)
Itching 0 3 0 3 (3)
Tinnitus 2 1 0 3 (3)
Heartburn 0 2 1 3 (3)
Infections 0 1 2 3 (3)
Other 7 12 6 25 (23)
Total (%) 31 (28) 53 (48) 26 (24) 110 (100)
Figure 2 Minocycline and doxycycline side effects by organ system and severity. Percentage of (a) minocycline and (b) doxycycline side
effects by organ system and severity. CNS, central nervous system; GI, gastrointestinal; HEENT, Head Eyes Ears Nose Throat.






Discontinued (%) 38.2 42.7




Doctor visit (%) 48.2 59.5
Missed work (%) 1.1 6.8
Hospitalized (%) 1.0 1.3
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two to eight other DMARDs [26]. Although statistically
significant, it is unlikely that small differences in age,
race, physical component summary score, and insurance
type are clinically relevant. These findings suggest that
providers have not embraced tetracyclines as primary
treatment options for RA and reserve their use primarily
as salvage therapy in patients with long-standing disease
that have failed other agents. These results stand in con-
trast to double-blind, placebo-controlled trials in early,
DMARD-naïve RA patients in which minocycline
resulted in significant short-term disease improvement
[10] and long-term remission [11], and proved more
efficacious than hydroxychloroqine [12]. Likewise, doxy-
cycline in combination with methotrexate has proven
more efficacious than methotrexate monotherapy [15].
Moreover, results of a meta-analysis of tetracyclines
found meaningful effects on tender and swollen joint
counts, erythrocyte sedimentation rate, and patient-
reported pain [16], comparable with hydroxychloroquine
[27], sulfasalazine [28], and gold [29].
Contemporary studies of minocycline and doxycycline
in RA coincided with the emergence of biologics. Rheu-
matologists now have an expanding arsenal of these
potent agents available, in addition to conventional
DMARDs. Antibiotics are generally considered late in
the disease process after other standard treatments have
failed. While we do not argue that minocycline and dox-
ycycline should be used as first-line agents, they should
be considered with other second-line DMARDs as
options for combination therapy with methotrexate and
for patients who are reticent to try conventional thera-
pies or cannot afford them. Additionally, recent research
into the possible role of oral filamentous bacteria in the
pathogenesis of RA may renew interest in the therapeu-
tic role of antibiotics [30-34].
Despite concerns about drug toxicity, the current study
found that minocycline and doxycycline are generally
well tolerated. Side effects were reported by only 17.8%
of minocycline users and 11.8% of doxycycline users,
most of which were of moderate severity. Less than one-
half of these patients discontinued minocycline or doxy-
cycline because of side effects, suggesting that they are at
least as well tolerated as other second-line RA medica-
tions, for which drug toxicity causes discontinuation in
15% of all patients [35]. For minocycline, cutaneous side
effects were the most common, accounting for over one-
half of all patient reports. This is consistent with previous
research, in which hyperpigmentation has been reported
in 40% of chronic minocycline users [36,37]. Since we did
not have dedicated coding for hyperpigmentation, we
speculate that this side effect was variously reported as
skin, other, photosensitivity, purpura, and rash. Dizziness
was reported less frequently than in previous reports,
accounting for only about 10% of all reported side effects
[8,9,38]. Doxycycline side effects were also similar to
other studies, with gastrointestinal and skin manifesta-
tions being most common [38]. Interestingly, dizziness
was nearly as common with doxycycline use (8.2%) as
with minocycline (9.5%).
Nearly one in five rheumatologists had prescribed
minocycline or doxycycline, and about 10% of patients
had used them at some point in their disease course.
However, most doctors had only prescribed these treat-
ments for one or two patients. Although we do not have
data to explain this pattern, it is possible that tetracy-
clines are used to treat a niche population of RA
patients, such as those who are reticent to try more con-
ventional DMARDs for fear of potential toxicities or
those who may have requested from their physician an
antibiotic-based treatment. The median duration of min-
ocycline (6 months) and doxycycline (3 months) treat-
ment was shorter than for other second-line DMARDs
[39]. This is not surprising given that our cohort had
long-standing, refractory disease, thus limiting the effi-
cacy of any treatment option. Additionally, short-term
use of minocycline and doxycycline for treatment of
infectious processes may have skewed our results. For
those who initiated minocycline or doxycycline during
NDB observation, 28% were stopped following the first
month of treatment, with side effects accounting for
17% of these discontinuations. Since it is unlikely that
minocycline and doxycycline would be stopped so
quickly if initiated as DMARDs, some patients probably
received these drugs for short-term antibiotic use. When
patients with courses of minocycline and doxycycline
equal to or less than 30 days were eliminated via a sen-
sitivity analysis (n = 133), however, the sociodemo-
graphic and disease characteristic results were not
meaningfully changed (data not shown). Excluding
patients with 1 month or less of treatment had only
modest effects on the median duration of minocycline
(7 months) and doxycycline (6 months) therapy.
The present study had several limitations. In the ana-
lysis of socioeconomic and disease characteristics, mino-
cycline and doxycycline users were combined to
improve power. These two groups possibly have distinc-
tive qualities, although there were no significant differ-
ences when we compared minocycline and doxycycline
users with one another (data not shown). The current
analysis also did not have access to laboratory markers
such as the rheumatoid factor status of patients; seropo-
sitivity may be predictive of minocycline and doxycy-
cline efficacy in early RA [10-12,15], thus impacting
timing of drug initiation. Finally, our findings may not
be generalizable to racial/ethnic minorities as Caucasian
patients made up about 90% of our cohort, with African
Americans and Hispanic patients accounting for 4.7%
and 2.9% of the sample, respectively. Despite these
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limitations, this is to our knowledge the first study to
examine minocycline and doxycycline use in a large
number of community-dwelling RA patients. Most clini-
cal trials of minocycline and doxycycline in RA have
been fairly small, and systematic reviews of drug toxici-
ties have relied upon case reports and trials with diverse
dosing strategies, patient populations, and drug indica-
tions. By focusing on community-dwelling patients, we
were able to investigate the real-world application of tet-
racycline therapy in RA.
Conclusions
In summary, these data provide evidence that rheuma-
tologists have not embraced minocycline and doxycy-
cline as primary treatment options for early, DMARD-
naïve RA. Patients initiating minocycline or doxycycline
therapy tend to have longer disease duration, more pre-
dnisone use, and exposure to a greater number of
DMARDs, which suggests long-standing, refractory dis-
ease. While minocycline or doxycycline is prescribed by
one in five rheumatologists, most use them infrequently
in only one to two RA patients. The duration of mino-
cycline and doxycycline therapy was 6 months and 3
months, respectively. Both minocycline and doxycycline
are generally well tolerated, with skin abnormalities,
nausea, and dizziness being the most common patient-
reported side effects.
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